Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine--studies in an experimental model for migraine.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000037:antagonists & inhibitors; D002339:Carotid Arteries / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003000:Clonidine / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D004878:Ergotamine / Q000494:pharmacology / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists; D008784:Methysergide / Q000494:pharmacology; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009638:Norepinephrine / Q000494:pharmacology; D012702:Serotonin Antagonists; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents
D000317:Adrenergic alpha-Antagonists; D006634:Histamine H1 Antagonists; D012702:Serotonin Antagonists; D014662:Vasoconstrictor Agents; D003000:Clonidine; D004878:Ergotamine; D001920:Bradykinin; D009638:Norepinephrine; D008784:Methysergide